


LIVE WEBINAR ON GROWTH DISORDERS

Recognition and Diagnosis





Webinar 1

The diagnostic approach
to short stature

Thursday, 9 December 2021

from 18:00 to 19:00 SGT (*Singapore Time*)

from 11:00 to 12:00 CET



OVERVIEW

Research and development in growth disorders has predominantly been in Western countries of relatively high income, even though growth disorders are prevalent globally. Diagnosis, treatment and monitoring guidelines for growth disorders are applicable to all countries, with the exception of race-specific growth charts, which should be local.

This series of four webinars will cover all aspects of diagnosis and treatment of the major short stature disorders. The definition and diagnosis of short stature will be described, together with the most common syndromes that have growth deficiency as one of their symptoms, and notably those which are approved by the FDA or EMA for treatment with recombinant human growth hormone (rhGH). rhGH therapy will be described in detail from its aims and objectives, initiation of therapy, dosage and monitoring to the responses in the most common disorders. Therapeutic outcome will be described. Many children (and adults) can be on rhGH therapy for extended periods of time, raising the issue of safety. This will be discussed, as will adherence to treatment, and the use of rhGH into adulthood, particularly in patients with severe GH deficiency and Prader-Willi syndrome.

LEARNING OBJECTIVES

After attending the live Webinar 1. 'The diagnostic approach to short stature', participants will understand:

- The definition of short stature
- The different aetiologies of short stature
- The types of short stature, ie normal variants of growth, true pathological short stature
- The regulation of normal childhood linear growth from hormonal modulation to growth plate chondrogenesis
- The clinical, biochemical (hormonal) and genetic assessment of the short child in the out-patient consultation setting
- The importance of commitment to a diagnosis in order to optimize management and therapeutic options

On completing the webinar series, participants will have a detailed understanding of the clinical field of growth disorders. All common growth disorders will be explained from the aetiological, investigational and therapeutic aspects. Participants will have gained knowledge in the art of clinical assessment as well as the science of investigational priorities. The therapeutic options will have been discussed with participants who will have learned how to judge whether rhGH therapy is indicated and to what extent it can be guaranteed to produce therapeutic benefit. Long-term outcomes will have been discussed and through live discussions the pros and cons of therapy will be debated. The importance of evidence-based assessment compared to anecdotal accounts will be understood. Participants will have gained a new insight into the management of growth disorders and in some cases, eg adult GH deficiency, therapeutic benefits in adult life will be debated. Transitional care of the GH deficient adolescent, compared to the patient with Turner syndrome will also be discussed.

TARGET AUDIENCE

This activity is designed for Pediatricians, Pediatric Endocrinologists and General Practitioners from the Asia Pacific Region.

LANGUAGE

The official language of this live educational conference is English.

REGISTRATION

The attendance to this webinar is free of charge, however registration is requested to participate. For registration, click here:

<https://cme-learning.scientificseminars.com/course/live-webinars-on-growth-disorders>

and complete a very short survey covering your current knowledge of the subject matter prior to attending the webinar.

CONTINUING MEDICAL EDUCATION

The diagnostic approach to short stature, Rome, Italy, 9/12/2021 - 9/12/2021

has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with **1 European CME credit (ECMEC®)**. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.



CME PROVIDER

Scientific Seminars International Foundation

Program Manager: Annamaria Nesticò

T +39 380 1504116 - F +39 06 4827169

info@scientificseminars.com

SCIENTIFIC ORGANIZER AND SPEAKER

Martin O. Savage

Emeritus Professor of Pediatric Endocrinology
The William Harvey Research Institute
Barts and the London School of Medicine & Dentistry,
Queen Mary University of London,
London, United Kingdom



Martin Savage is Emeritus Professor of Paediatric Endocrinology at William Harvey Research Institute, Barts and the London School of Medicine & Dentistry, Queen Mary, University of London. He was head of the Paediatric Endocrine Unit at Barts and the London School of Medicine from 1982 to 2007. He is a clinician with clinical and research interests in growth disorders, specifically those with abnormalities in the growth hormone-IGF-1 axis. His main research field has been the phenotype- genotype relationships of GH-IGF-1 axis defects, notably GH resistance. He published the first human case of an IGF-1 gene defect in the New England Journal of Medicine in 1996. His other clinical interests are Cushing's syndrome and growth in chronic inflammatory diseases. He was General Secretary of the European Society for Paediatric Endocrinology (ESPE) from 1997 to 2004. Professor Savage has lectured in 60 countries worldwide and has published more than 460 original articles, reviews, textbook chapters and books. In 2007, he was awarded the ESPE Andrea Prader Prize for contributions to paediatric endocrinology and in 2018 he received a Visionary Award from the American Human Growth Foundation. He continues to lecture nationally and internationally.

THURSDAY, 9 DECEMBER 2021
FROM 18:00 TO 19:00 SGT (SINGAPORE TIME)

18.00		Welcome and introduction
18.05	A	Normal and abnormal growth • Endocrine regulation of linear growth - GH-IGF-I axis and growth plate chondrogenesis • Definition of short stature - Difference between true pathological short stature and normal variants of growth • Causes of short stature - Primary growth disorders (primary defects of chondrogenesis, eg growth plate defects) - Secondary growth disorders (hormonal, environmental defects of chondrogenesis)
18.20	B	Referral and clinical assessment • Indications for referral • Protocol for assessment - Clinical assessment - History, examination - Dysmorphic f
18.30	C	Diagnostic investigations • Biochemical investigations - General paediatric screening tests endocrine, genetic - Hormonal assessment (GH- IGF-I axis) - Genetic investigations • Commitment to diagnosis • Conclusions
18.40		Q & A, General Interactive Discussion with participants
18.55		Closing remarks
19.00		End of the live webinar



FACULTY DISCLOSURE

Scientific Seminars International Foundation adheres to guidelines of the European Accreditation Council for Continuing Medical Education (EACCME®) and all other professional organizations, as applicable, which state that programs awarding continuing education credits must be balanced, independent, objective and scientifically rigorous. Investigative and other uses for pharmaceutical agents, medical devices and other products (other than those uses indicated in approved product labelling/package insert for the product) may be presented in the program (which may reflect clinical experience, the professional literature or other clinical sources known to the presenter). We ask all presenters to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is only intended to inform participants of any potential conflicts so that participants may form their own judgements, based on full disclosure of the facts. Further, all opinions and recommendations presented during the program and all program-related materials neither imply an endorsement nor a recommendation on the part of Scientific Seminars International Foundation. All presentations represent solely the independent views of the presenters/authors.

The following faculty provided information regarding significant commercial relationships and/or discussions of investigational or non-EMEA/FDA approved (off-label) uses of drugs:

Martin Savage Declared receipt of honoraria or consultation fees from OPKO, Pfizer, Sandoz, Merck Healthcare KGaA Darmstadt, Germany, Springer-Nature IME, Visen and participation in IPSEN and Novo Nordisk speaker's bureau.



All Scientific Seminars International Foundation programs are organized solely to promote the exchange and dissemination of scientific and medical information. No forms of promotional activities are permitted. There may be presentations discussing investigational uses of various products. These views are the responsibility of the named speakers, and do not represent an endorsement or recommendation on the part of Scientific Seminars International Foundation. This independent educational program is made possible thanks to an educational grant received from Merck Healthcare KGaA Darmstadt Germany.



Scientific Seminars International Foundation
Via di Porta Pinciana, 6 - 00187 Roma
www.scientificseminars.com

Copyright © Scientific Seminars International Foundation, 2021. All rights reserved.